Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC
→ Tokyo’s Astellas Pharma has inked a licensing deal with Vancouver’s Aquinox Pharmaceutical, snagging development and commercialization rights for Aquinox’s lead drug candidate rosiptor in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.